Relay Therapeutics, Inc. (RLAY) Misses Q2 EPS by 1c, misses on revenue

Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q2 EPS of ($0.81), $0.01 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $120 thousand versus the consensus estimate of $719.44 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Relay Therapeutics (RLAY) PT Raised to $31 at JPMorgan
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c